Cobra Biologics and BioCancell Collaborate on Cancer Therapy Drug
Cobra Biologics and BioCancell announce an agreement to manufacture BioCancell's BC-821 cancer drug.
Cobra Biologics, a contract manufacturer of clinical and commercial scale biologics and pharmaceuticals, and BioCancell have announced an agreement to manufacture BioCancell’s BC-821 cancer drug for clinical trials.
BioCancell’s Phase I clinical trial for BC-821, scheduled to launch in 2015, is a result of pre-clinical studies that examined the use of BC-821 as a treatment for several cancer indications such as non-small-celllung carcinoma, ovarian cancer, glioblastoma (brain tumour), and liver metastasis.
Cobra will provide GMP manufacture of BC-821 plasmid DNA, and fill and finish the product in accordance with aseptic manufacturing procedures before releasing it for clinical trials.
BC-821 is a potential therapeutic product that penetrates cancerous cells and activates the synthesis of DTA under the control of H19 and/or P4 promoter of the target gene IGF2. Both H19 and P4-IGF2 transcriptionfactors are expressed only in cancerous cells. An international patent application for this product was filed by BioCancell in 2008.
Source: Cobra Biologics
EMA Recommends Imfinzi-Based Perioperative Regimen for Treating Resectable NSCLC
March 10th 2025The committee’s recommendation is based on results from a Phase III trial in which Imfinzi demonstrated a reduced risk of recurrence, progression, or death by 32% compared to neoadjuvant chemotherapy alone.
